Physician profile
John E Pantano
NPI 1679524201
$12,666.53
in general payments reported to CMS, 2019-2025
35 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $947 · 2021: $1,806 · 2022: $2,799 · 2023: $3,043 · 2024: $1,514 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,820 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,820.29 |
| Education | $117.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,605.76 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $2,505.55 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,708.67 | 2019-2024 | Airsupra, Breztri, Fasenra |
| Mylan Specialty L.P. | $894.78 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $592.75 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $558.53 | 2021-2024 | Glassia |
| Jazz Pharmaceuticals INC. | $511.57 | 2019-2024 | |
| Grifols USA, LLC | $508.34 | 2019-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $465.62 | 2021-2024 | Acthar |
| Electromed, INC. | $305.02 | 2019-2024 | Smartvest |
| Pfizer INC. | $299.95 | 2019-2024 | |
| Harmony Biosciences LLC | $246.46 | 2020-2023 | Wakix |
| Shionogi INC | $177.08 | 2022-2023 | Fetroja |
| Baxter Healthcare | $174.95 | 2021-2022 | |
| Pulmonx Corporation | $139.57 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $136.03 | 2022 | |
| United Therapeutics Corporation | $120.84 | 2025 | |
| Sunovion Pharmaceuticals INC. | $113.54 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $107.23 | 2023-2024 | Lumryz |
| Axsome Therapeutics, INC. | $82.62 | 2023 | Sunosi |
| Vanda Pharmaceuticals INC. | $66.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $47.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.26 | 2023 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $37.63 | 2019-2021 | |
| Vapotherm INC | $37.43 | 2021-2022 | |
| Insmed, INC. | $35.45 | 2024-2025 | Brinsupri, Arikayce |
| Paratek Pharmaceuticals, INC. | $33.60 | 2022 | |
| Amgen INC. | $16.53 | 2022 | |
| Melinta Therapeutics, LLC | $15.83 | 2019 | |
| Ceribell, INC. | $15.66 | 2024 | Pocket Eeg Device |
| Philips North America LLC | $14.37 | 2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $13.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.21 | 2019 | |
| Eisai INC. | $12.99 | 2021 | |
| Corium, LLC | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pantano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.